Compare Rivian Automotive, Inc. (RIVN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RIVN | ZBH | |
|---|---|---|
Market Cap | $20.75B | $16.95B |
Volume | 26,144,654 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $103.98 |
52-Week Low | $12.50 | $79.58 |
Typical Hold Time | 61 Days | 89 Days |
Enterprise Value | $20.79B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian (RIVN) trades at $14.33, down 0.07% on the day, with a bearish technical signal from moving averages. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates, but maintained full-year guidance, causing mixed market reactions. Financially, revenue growth continues while losses narrow, with a net income margin of -54.95% in 2025. Analyst consensus is a Buy with a $16.89 price target, though cash burn remains a concern with negative operating cash flow.
Rivian's outlook hinges on scaling R2 production and advancing autonomy, offering growth potential, but high cash burn, competitive pressures, and execution risks pose significant challenges. The stock presents a speculative opportunity for investors betting on EV adoption and operational improvements, balanced by substantial financial and market volatility risks.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
